3353

معلومات اساسية

• متاح على:
• English
• العربية

The EarlyTect Colon Cancer Test is a highly reliable and approved screening method that has been endorsed by the Korea Ministry of Food and Drug Safety. Extensive clinical trials were conducted at renowned medical facilities, including Yonsei Medical Center, Severance Hospital, and Severance Check-up Center, involving 585 individuals aged 30 to 80. These trials demonstrated that the test has a remarkable accuracy of 90% in diagnosing colorectal cancer (CRC) through the analysis of fecal DNA. By employing qualitative real-time PCR technology, the EarlyTect test measures the presence of methylated Syndecan-2, a biomarker closely associated with the development of precancerous lesions in CRC, thereby enabling the early detection of colorectal cancer.

It is important to note that the EarlyTect Colon Cancer Test is intended for screening purposes only and is not meant to definitively confirm the presence of colorectal cancer. If a subject tests positive, it indicates that CRC or precancerous lesions may potentially be present, thus necessitating further diagnostic investigations.

Product Standard:
- Cancer Type: Colorectal Cancer
- Intended Subject: Asymptomatic individuals seeking colorectal cancer screening
- Biomarker: SDC2 methylation

We offer flexible pricing options and transaction conditions that are open for negotiation. For specific details regarding pricing and purchasing, kindly request a quote.

Please let us know if you have any further inquiries or require additional information.